Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Contemporary clinical profile and outcome of prosthetic valve endocarditis

Identifieur interne : 002388 ( PascalFrancis/Curation ); précédent : 002387; suivant : 002389

Contemporary clinical profile and outcome of prosthetic valve endocarditis

Auteurs : Andrew Wang [États-Unis] ; Eugene Athan [Australie] ; Paul A. Pappas [États-Unis] ; Vance G. Jr Fowler [États-Unis] ; Lars Olaison [Suède] ; Carlos Pare [Espagne] ; Benito Almirante [Espagne] ; Patricia Munoz [Espagne] ; Marco Rizzi [Italie] ; Christoph Naber [Allemagne] ; Mateja Logar [Slovénie] ; Pierre Tattevin [France] ; Diana L. Iarussi [Italie] ; Christine Selton-Suty [France] ; Sandra Braun Jones [Chili] ; José Casabe [Argentine] ; Arthur Morris [Nouvelle-Zélande] ; Ralph Corey [États-Unis] ; Christopher H. Cabell [États-Unis]

Source :

RBID : Pascal:07-0191068

Descripteurs français

English descriptors

Abstract

Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.
pA  
A01 01  1    @0 0098-7484
A03   1    @0 JAMA j. Am. Med. Assoc.
A05       @2 297
A06       @2 12
A08 01  1  ENG  @1 Contemporary clinical profile and outcome of prosthetic valve endocarditis
A11 01  1    @1 WANG (Andrew)
A11 02  1    @1 ATHAN (Eugene)
A11 03  1    @1 PAPPAS (Paul A.)
A11 04  1    @1 FOWLER (Vance G. JR)
A11 05  1    @1 OLAISON (Lars)
A11 06  1    @1 PARE (Carlos)
A11 07  1    @1 ALMIRANTE (Benito)
A11 08  1    @1 MUNOZ (Patricia)
A11 09  1    @1 RIZZI (Marco)
A11 10  1    @1 NABER (Christoph)
A11 11  1    @1 LOGAR (Mateja)
A11 12  1    @1 TATTEVIN (Pierre)
A11 13  1    @1 IARUSSI (Diana L.)
A11 14  1    @1 SELTON-SUTY (Christine)
A11 15  1    @1 BRAUN JONES (Sandra)
A11 16  1    @1 CASABE (José)
A11 17  1    @1 MORRIS (Arthur)
A11 18  1    @1 COREY (Ralph)
A11 19  1    @1 CABELL (Christopher H.)
A14 01      @1 Department of Medicine, Duke University Medical Center @2 Durham, NC @3 USA @Z 1 aut. @Z 4 aut. @Z 18 aut. @Z 19 aut.
A14 02      @1 Department of Infectious Disease, The Geelong Hospital at the University of Melbourne @2 Melbourne @3 AUS @Z 2 aut.
A14 03      @1 Outcomes Research and Assessment Group, Duke Clinical Research Institute @2 Durham, NC @3 USA @Z 3 aut.
A14 04      @1 Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra @2 Göteborg @3 SWE @Z 5 aut.
A14 05      @1 Department of Cardiology, University of Barcelona @2 Barcelona @3 ESP @Z 6 aut.
A14 06      @1 Infectious Diseases Department, Hospital Universitari Vall d'Hebron @2 Barcelona @3 ESP @Z 7 aut.
A14 07      @1 Department of Infectious Disease, Hospital General Universitario Gregorio Maranon @2 Barcelona @3 ESP @Z 8 aut.
A14 08      @1 Department of Infectious Disease, Ospedali Riuniti @2 Bergamo @3 ITA @Z 9 aut.
A14 09      @1 Cardiology Clinic, University Essen @2 Essen @3 DEU @Z 10 aut.
A14 10      @1 Department of Infectious Disease, Medical Center Ljublijana @2 Ljublijana @3 SVN @Z 11 aut.
A14 11      @1 Department of Infec tious Disease, Pontchaillou University @2 Rennes @3 FRA @Z 12 aut.
A14 12      @1 Department of Cardiology, II Universita di Napoli @2 Naples @3 ITA @Z 13 aut.
A14 13      @1 Cardiology Service, CHU Nancy-Brabois @2 Nancy @3 FRA @Z 14 aut.
A14 14      @1 Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile @2 Santiago @3 CHL @Z 15 aut.
A14 15      @1 Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro @2 Buenos Aires @3 ARG @Z 16 aut.
A14 16      @1 Diagnostic Medlab, Auckland City Hospital @2 Auckland @3 NZL @Z 17 aut.
A20       @1 1354-1361
A21       @1 2007
A23 01      @0 ENG
A43 01      @1 INIST @2 5051 @5 354000145706680070
A44       @0 0000 @1 © 2007 INIST-CNRS. All rights reserved.
A45       @0 41 ref.
A47 01  1    @0 07-0191068
A60       @1 P
A61       @0 A
A64 01  1    @0 JAMA, the journal of the American Medical Association
A66 01      @0 USA
C01 01    ENG  @0 Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.
C02 01  X    @0 002B01
C02 02  X    @0 002B25I
C02 03  X    @0 002B12A04
C03 01  X  FRE  @0 Prothèse @5 01
C03 01  X  ENG  @0 Prosthesis @5 01
C03 01  X  SPA  @0 Prótesis @5 01
C03 02  X  FRE  @0 Symptomatologie @5 02
C03 02  X  ENG  @0 Symptomatology @5 02
C03 02  X  SPA  @0 Sintomatología @5 02
C03 03  X  FRE  @0 Evolution @5 03
C03 03  X  ENG  @0 Evolution @5 03
C03 03  X  SPA  @0 Evolución @5 03
C03 04  X  FRE  @0 Endocardite @5 04
C03 04  X  ENG  @0 Endocarditis @5 04
C03 04  X  SPA  @0 Endocarditis @5 04
C03 05  X  FRE  @0 Pronostic @5 05
C03 05  X  ENG  @0 Prognosis @5 05
C03 05  X  SPA  @0 Pronóstico @5 05
C03 06  X  FRE  @0 Valvule cardiaque @5 06
C03 06  X  ENG  @0 Heart valve @5 06
C03 06  X  SPA  @0 Válvula cardíaca @5 06
C03 07  X  FRE  @0 Médecine @5 08
C03 07  X  ENG  @0 Medicine @5 08
C03 07  X  SPA  @0 Medicina @5 08
C07 01  X  FRE  @0 Appareil circulatoire pathologie @5 37
C07 01  X  ENG  @0 Cardiovascular disease @5 37
C07 01  X  SPA  @0 Aparato circulatorio patología @5 37
C07 02  X  FRE  @0 Cardiopathie @5 38
C07 02  X  ENG  @0 Heart disease @5 38
C07 02  X  SPA  @0 Cardiopatía @5 38
C07 03  X  FRE  @0 Endocarde pathologie @5 39
C07 03  X  ENG  @0 Endocardial disease @5 39
C07 03  X  SPA  @0 Endocardio patología @5 39
N21       @1 128
N44 01      @1 OTO
N82       @1 OTO

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:07-0191068

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Contemporary clinical profile and outcome of prosthetic valve endocarditis</title>
<author>
<name sortKey="Wang, Andrew" sort="Wang, Andrew" uniqKey="Wang A" first="Andrew" last="Wang">Andrew Wang</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Athan, Eugene" sort="Athan, Eugene" uniqKey="Athan E" first="Eugene" last="Athan">Eugene Athan</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Infectious Disease, The Geelong Hospital at the University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author>
<name sortKey="Pappas, Paul A" sort="Pappas, Paul A" uniqKey="Pappas P" first="Paul A." last="Pappas">Paul A. Pappas</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Outcomes Research and Assessment Group, Duke Clinical Research Institute</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Fowler, Vance G Jr" sort="Fowler, Vance G Jr" uniqKey="Fowler V" first="Vance G. Jr" last="Fowler">Vance G. Jr Fowler</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Olaison, Lars" sort="Olaison, Lars" uniqKey="Olaison L" first="Lars" last="Olaison">Lars Olaison</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author>
<name sortKey="Pare, Carlos" sort="Pare, Carlos" uniqKey="Pare C" first="Carlos" last="Pare">Carlos Pare</name>
<affiliation wicri:level="1">
<inist:fA14 i1="05">
<s1>Department of Cardiology, University of Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author>
<name sortKey="Almirante, Benito" sort="Almirante, Benito" uniqKey="Almirante B" first="Benito" last="Almirante">Benito Almirante</name>
<affiliation wicri:level="1">
<inist:fA14 i1="06">
<s1>Infectious Diseases Department, Hospital Universitari Vall d'Hebron</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author>
<name sortKey="Munoz, Patricia" sort="Munoz, Patricia" uniqKey="Munoz P" first="Patricia" last="Munoz">Patricia Munoz</name>
<affiliation wicri:level="1">
<inist:fA14 i1="07">
<s1>Department of Infectious Disease, Hospital General Universitario Gregorio Maranon</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author>
<name sortKey="Rizzi, Marco" sort="Rizzi, Marco" uniqKey="Rizzi M" first="Marco" last="Rizzi">Marco Rizzi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="08">
<s1>Department of Infectious Disease, Ospedali Riuniti</s1>
<s2>Bergamo</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author>
<name sortKey="Naber, Christoph" sort="Naber, Christoph" uniqKey="Naber C" first="Christoph" last="Naber">Christoph Naber</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Cardiology Clinic, University Essen</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author>
<name sortKey="Logar, Mateja" sort="Logar, Mateja" uniqKey="Logar M" first="Mateja" last="Logar">Mateja Logar</name>
<affiliation wicri:level="1">
<inist:fA14 i1="10">
<s1>Department of Infectious Disease, Medical Center Ljublijana</s1>
<s2>Ljublijana</s2>
<s3>SVN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Slovénie</country>
</affiliation>
</author>
<author>
<name sortKey="Tattevin, Pierre" sort="Tattevin, Pierre" uniqKey="Tattevin P" first="Pierre" last="Tattevin">Pierre Tattevin</name>
<affiliation wicri:level="1">
<inist:fA14 i1="11">
<s1>Department of Infec tious Disease, Pontchaillou University</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Iarussi, Diana L" sort="Iarussi, Diana L" uniqKey="Iarussi D" first="Diana L." last="Iarussi">Diana L. Iarussi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="12">
<s1>Department of Cardiology, II Universita di Napoli</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author>
<name sortKey="Selton Suty, Christine" sort="Selton Suty, Christine" uniqKey="Selton Suty C" first="Christine" last="Selton-Suty">Christine Selton-Suty</name>
<affiliation wicri:level="1">
<inist:fA14 i1="13">
<s1>Cardiology Service, CHU Nancy-Brabois</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Braun Jones, Sandra" sort="Braun Jones, Sandra" uniqKey="Braun Jones S" first="Sandra" last="Braun Jones">Sandra Braun Jones</name>
<affiliation wicri:level="1">
<inist:fA14 i1="14">
<s1>Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile</s1>
<s2>Santiago</s2>
<s3>CHL</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Chili</country>
</affiliation>
</author>
<author>
<name sortKey="Casabe, Jose" sort="Casabe, Jose" uniqKey="Casabe J" first="José" last="Casabe">José Casabe</name>
<affiliation wicri:level="1">
<inist:fA14 i1="15">
<s1>Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
</affiliation>
</author>
<author>
<name sortKey="Morris, Arthur" sort="Morris, Arthur" uniqKey="Morris A" first="Arthur" last="Morris">Arthur Morris</name>
<affiliation wicri:level="1">
<inist:fA14 i1="16">
<s1>Diagnostic Medlab, Auckland City Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author>
<name sortKey="Corey, Ralph" sort="Corey, Ralph" uniqKey="Corey R" first="Ralph" last="Corey">Ralph Corey</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Cabell, Christopher H" sort="Cabell, Christopher H" uniqKey="Cabell C" first="Christopher H." last="Cabell">Christopher H. Cabell</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">07-0191068</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0191068 INIST</idno>
<idno type="RBID">Pascal:07-0191068</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003D00</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002388</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Contemporary clinical profile and outcome of prosthetic valve endocarditis</title>
<author>
<name sortKey="Wang, Andrew" sort="Wang, Andrew" uniqKey="Wang A" first="Andrew" last="Wang">Andrew Wang</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Athan, Eugene" sort="Athan, Eugene" uniqKey="Athan E" first="Eugene" last="Athan">Eugene Athan</name>
<affiliation wicri:level="1">
<inist:fA14 i1="02">
<s1>Department of Infectious Disease, The Geelong Hospital at the University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author>
<name sortKey="Pappas, Paul A" sort="Pappas, Paul A" uniqKey="Pappas P" first="Paul A." last="Pappas">Paul A. Pappas</name>
<affiliation wicri:level="1">
<inist:fA14 i1="03">
<s1>Outcomes Research and Assessment Group, Duke Clinical Research Institute</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Fowler, Vance G Jr" sort="Fowler, Vance G Jr" uniqKey="Fowler V" first="Vance G. Jr" last="Fowler">Vance G. Jr Fowler</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Olaison, Lars" sort="Olaison, Lars" uniqKey="Olaison L" first="Lars" last="Olaison">Lars Olaison</name>
<affiliation wicri:level="1">
<inist:fA14 i1="04">
<s1>Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Suède</country>
</affiliation>
</author>
<author>
<name sortKey="Pare, Carlos" sort="Pare, Carlos" uniqKey="Pare C" first="Carlos" last="Pare">Carlos Pare</name>
<affiliation wicri:level="1">
<inist:fA14 i1="05">
<s1>Department of Cardiology, University of Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author>
<name sortKey="Almirante, Benito" sort="Almirante, Benito" uniqKey="Almirante B" first="Benito" last="Almirante">Benito Almirante</name>
<affiliation wicri:level="1">
<inist:fA14 i1="06">
<s1>Infectious Diseases Department, Hospital Universitari Vall d'Hebron</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author>
<name sortKey="Munoz, Patricia" sort="Munoz, Patricia" uniqKey="Munoz P" first="Patricia" last="Munoz">Patricia Munoz</name>
<affiliation wicri:level="1">
<inist:fA14 i1="07">
<s1>Department of Infectious Disease, Hospital General Universitario Gregorio Maranon</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author>
<name sortKey="Rizzi, Marco" sort="Rizzi, Marco" uniqKey="Rizzi M" first="Marco" last="Rizzi">Marco Rizzi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="08">
<s1>Department of Infectious Disease, Ospedali Riuniti</s1>
<s2>Bergamo</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author>
<name sortKey="Naber, Christoph" sort="Naber, Christoph" uniqKey="Naber C" first="Christoph" last="Naber">Christoph Naber</name>
<affiliation wicri:level="1">
<inist:fA14 i1="09">
<s1>Cardiology Clinic, University Essen</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author>
<name sortKey="Logar, Mateja" sort="Logar, Mateja" uniqKey="Logar M" first="Mateja" last="Logar">Mateja Logar</name>
<affiliation wicri:level="1">
<inist:fA14 i1="10">
<s1>Department of Infectious Disease, Medical Center Ljublijana</s1>
<s2>Ljublijana</s2>
<s3>SVN</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Slovénie</country>
</affiliation>
</author>
<author>
<name sortKey="Tattevin, Pierre" sort="Tattevin, Pierre" uniqKey="Tattevin P" first="Pierre" last="Tattevin">Pierre Tattevin</name>
<affiliation wicri:level="1">
<inist:fA14 i1="11">
<s1>Department of Infec tious Disease, Pontchaillou University</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Iarussi, Diana L" sort="Iarussi, Diana L" uniqKey="Iarussi D" first="Diana L." last="Iarussi">Diana L. Iarussi</name>
<affiliation wicri:level="1">
<inist:fA14 i1="12">
<s1>Department of Cardiology, II Universita di Napoli</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author>
<name sortKey="Selton Suty, Christine" sort="Selton Suty, Christine" uniqKey="Selton Suty C" first="Christine" last="Selton-Suty">Christine Selton-Suty</name>
<affiliation wicri:level="1">
<inist:fA14 i1="13">
<s1>Cardiology Service, CHU Nancy-Brabois</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author>
<name sortKey="Braun Jones, Sandra" sort="Braun Jones, Sandra" uniqKey="Braun Jones S" first="Sandra" last="Braun Jones">Sandra Braun Jones</name>
<affiliation wicri:level="1">
<inist:fA14 i1="14">
<s1>Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile</s1>
<s2>Santiago</s2>
<s3>CHL</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>Chili</country>
</affiliation>
</author>
<author>
<name sortKey="Casabe, Jose" sort="Casabe, Jose" uniqKey="Casabe J" first="José" last="Casabe">José Casabe</name>
<affiliation wicri:level="1">
<inist:fA14 i1="15">
<s1>Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
</affiliation>
</author>
<author>
<name sortKey="Morris, Arthur" sort="Morris, Arthur" uniqKey="Morris A" first="Arthur" last="Morris">Arthur Morris</name>
<affiliation wicri:level="1">
<inist:fA14 i1="16">
<s1>Diagnostic Medlab, Auckland City Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>17 aut.</sZ>
</inist:fA14>
<country>Nouvelle-Zélande</country>
</affiliation>
</author>
<author>
<name sortKey="Corey, Ralph" sort="Corey, Ralph" uniqKey="Corey R" first="Ralph" last="Corey">Ralph Corey</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Cabell, Christopher H" sort="Cabell, Christopher H" uniqKey="Cabell C" first="Christopher H." last="Cabell">Christopher H. Cabell</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">JAMA, the journal of the American Medical Association</title>
<title level="j" type="abbreviated">JAMA j. Am. Med. Assoc.</title>
<idno type="ISSN">0098-7484</idno>
<imprint>
<date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">JAMA, the journal of the American Medical Association</title>
<title level="j" type="abbreviated">JAMA j. Am. Med. Assoc.</title>
<idno type="ISSN">0098-7484</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Endocarditis</term>
<term>Evolution</term>
<term>Heart valve</term>
<term>Medicine</term>
<term>Prognosis</term>
<term>Prosthesis</term>
<term>Symptomatology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Prothèse</term>
<term>Symptomatologie</term>
<term>Evolution</term>
<term>Endocardite</term>
<term>Pronostic</term>
<term>Valvule cardiaque</term>
<term>Médecine</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Médecine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0098-7484</s0>
</fA01>
<fA03 i2="1">
<s0>JAMA j. Am. Med. Assoc.</s0>
</fA03>
<fA05>
<s2>297</s2>
</fA05>
<fA06>
<s2>12</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Contemporary clinical profile and outcome of prosthetic valve endocarditis</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>WANG (Andrew)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>ATHAN (Eugene)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>PAPPAS (Paul A.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>FOWLER (Vance G. JR)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>OLAISON (Lars)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>PARE (Carlos)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>ALMIRANTE (Benito)</s1>
</fA11>
<fA11 i1="08" i2="1">
<s1>MUNOZ (Patricia)</s1>
</fA11>
<fA11 i1="09" i2="1">
<s1>RIZZI (Marco)</s1>
</fA11>
<fA11 i1="10" i2="1">
<s1>NABER (Christoph)</s1>
</fA11>
<fA11 i1="11" i2="1">
<s1>LOGAR (Mateja)</s1>
</fA11>
<fA11 i1="12" i2="1">
<s1>TATTEVIN (Pierre)</s1>
</fA11>
<fA11 i1="13" i2="1">
<s1>IARUSSI (Diana L.)</s1>
</fA11>
<fA11 i1="14" i2="1">
<s1>SELTON-SUTY (Christine)</s1>
</fA11>
<fA11 i1="15" i2="1">
<s1>BRAUN JONES (Sandra)</s1>
</fA11>
<fA11 i1="16" i2="1">
<s1>CASABE (José)</s1>
</fA11>
<fA11 i1="17" i2="1">
<s1>MORRIS (Arthur)</s1>
</fA11>
<fA11 i1="18" i2="1">
<s1>COREY (Ralph)</s1>
</fA11>
<fA11 i1="19" i2="1">
<s1>CABELL (Christopher H.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Medicine, Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>18 aut.</sZ>
<sZ>19 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Infectious Disease, The Geelong Hospital at the University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Outcomes Research and Assessment Group, Duke Clinical Research Institute</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Department of Infectious Disease, Sahlgrenska Universitetssjukhuset/ Ostra</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05">
<s1>Department of Cardiology, University of Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06">
<s1>Infectious Diseases Department, Hospital Universitari Vall d'Hebron</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07">
<s1>Department of Infectious Disease, Hospital General Universitario Gregorio Maranon</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08">
<s1>Department of Infectious Disease, Ospedali Riuniti</s1>
<s2>Bergamo</s2>
<s3>ITA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09">
<s1>Cardiology Clinic, University Essen</s1>
<s2>Essen</s2>
<s3>DEU</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="10">
<s1>Department of Infectious Disease, Medical Center Ljublijana</s1>
<s2>Ljublijana</s2>
<s3>SVN</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="11">
<s1>Department of Infec tious Disease, Pontchaillou University</s1>
<s2>Rennes</s2>
<s3>FRA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="12">
<s1>Department of Cardiology, II Universita di Napoli</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="13">
<s1>Cardiology Service, CHU Nancy-Brabois</s1>
<s2>Nancy</s2>
<s3>FRA</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="14">
<s1>Laboratorio de Tecnicas No Invasivas, Hospital Clinico Pont Universidad Catolica de Chile</s1>
<s2>Santiago</s2>
<s3>CHL</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="15">
<s1>Department of Cardiology, Institute de Cardiologia y Cirugia Cardiovascular, Fundacion Favaloro</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="16">
<s1>Diagnostic Medlab, Auckland City Hospital</s1>
<s2>Auckland</s2>
<s3>NZL</s3>
<sZ>17 aut.</sZ>
</fA14>
<fA20>
<s1>1354-1361</s1>
</fA20>
<fA21>
<s1>2007</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>5051</s2>
<s5>354000145706680070</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>41 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>07-0191068</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>JAMA, the journal of the American Medical Association</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Context Prosthetic valve endocarditis (PVE) is associated with significant mortality and morbidity. The contemporary clinical profile and outcome of PVE are not well defined. Objectives To describe the prevalence, clinical characteristics, and outcome of PVE, with attention to health care-associated infection, and to determine prognostic factors associated with in-hospital mortality. Design, Setting, and Participants Prospective, observational cohort study conducted at 61 medical centers in 28 countries, including 556 patients with definite PVE as defined by Duke University diagnostic criteria who were enrolled in the International Collaboration on Endocarditis-Prospective Cohort Study from June 2000 to August 2005. Main Outcome Measure In-hospital mortality. Results Definite PVE was present in 556 (20.1 %) of 2670 patients with infective endocarditis. Staphylococcus aureus was the most common causative organism (128 patients [23.0%]), followed by coagulase-negative staphylococci (94 patients [16.9%]). Health care-associated PVE was present in 203 (36.5%) of the overall cohort. Seventy-one percent of health care-associated PVE occurred within the first year of valve implantation, and the majority of cases were diagnosed after the early (60-day) period. Surgery was performed in 272 (48.9%) patients during the index hospitalization. In-hospital death occurred in 127 (22.8%) patients and was predicted by older age, health care-associated infection (62/203 [30.5%]; adjusted odds ratio [OR], 1.62; 95% confidence interval [Cl], 1.08-2.44; P=.02), S aureus infection (44/128 [34.4%]; adjusted OR, 1.73; 95% Cl, 1.01-2.95; P=.05), and complications of PVE, including heart failure (60/183 [32.8%]; adjusted OR, 2.33; 95% Cl, 1.62-3.34; P<.001), stroke (34/101 [33.7%]; adjusted OR, 2.25; 95% Cl, 1.25-4.03; P=.007), intracardiac abscess (47/144 [32.6%]; adjusted OR, 1.86; 95% Cl, 1.10-3.15; P=.02), and persistent bacteremia (27/49 [55.1 %]; adjusted OR, 4.29; 95% Cl, 1.99-9.22; P<.001). Conclusions Prosthetic valve endocarditis accounts for a high percentage of all cases of infective endocarditis in many regions of the world. Staphylococcus aureus is now the leading cause of PVE. Health care-associated infection significantly influences the clinical characteristics and outcome of PVE. Complications of PVE strongly predict in-hospital mortality, which remains high despite prompt diagnosis and the frequent use of surgical intervention.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B01</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B25I</s0>
</fC02>
<fC02 i1="03" i2="X">
<s0>002B12A04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Prothèse</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Prosthesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Prótesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Symptomatologie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Symptomatology</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Sintomatología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Evolution</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Evolution</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Evolución</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Endocardite</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Endocarditis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Endocarditis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Pronostic</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Prognosis</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Pronóstico</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Valvule cardiaque</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Heart valve</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Válvula cardíaca</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Médecine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Medicine</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Medicina</s0>
<s5>08</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Appareil circulatoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Cardiopathie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Heart disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Cardiopatía</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Endocarde pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Endocardial disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Endocardio patología</s0>
<s5>39</s5>
</fC07>
<fN21>
<s1>128</s1>
</fN21>
<fN44 i1="01">
<s1>OTO</s1>
</fN44>
<fN82>
<s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002388 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002388 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:07-0191068
   |texte=   Contemporary clinical profile and outcome of prosthetic valve endocarditis
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024